Novel Antisense Technology for Treating Epidermolysis Bullosa Simplex (Clinical Fellowship)

Project Details

StatusActive
Effective start/end date1/10/1531/12/20

Funding

  • (McLean 13): £119,823.00
  • (McLean 13 Year 3): £148,840.61
  • (Steensel/Mclean 1): £82,258.00